Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma

NCT02541149 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2015-09-04

No results posted yet for this study

Summary

This study aimed to investigate the clinical utility of Annexin A2 serum level as a novel diagnostic marker of hepatocellular carcinoma (HCC) and to correlate its level with alpha fetoprotein the current marker ofhepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

PROCEDURE

blood sample

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541149 on ClinicalTrials.gov